University of Washington News and Information
UW Office of News and Information
University of Washington
 

UWNEWS.ORG HOME

ABOUT UWNEWS.ORG
Mission
Contact Information
Office Location
Media Officers and Staff


UW NEWS BY CATEGORY
Health and Medicine
Science
Technology
Environment
Social Science
Business
Law and Policy
Politics and Government
Community
Education
Campus
Bothell and Tacoma
Arts and Humanities

UWNEWS.ORG RSS
Top RSS News Feeds
RSS by UW Unit
RSS by UW Expert

UW NEWS BY DATE
UW IN THE MEDIA
Local Coverage

OTHER UW NEWS
Health Sciences
UW Athletics

UW PUBLICATIONS
University Week
UW Annual Report
Columns
Fueling our Future
UW Daily
UW Graphic Standards

   
Oct. 14, 2004 | Science
UW licenses potential cancer treatment derived from ancient Chinese folk remedy
Rob Harrill    rharrill@u.washington.edu   
 
 
University of Washington
Attacking a killer: Human leukemia cells, pictured above, show the effects of a new artemisinin-based compound created by UW researchers and licensed to a Chinese company for development. The cell in the center has been destroyed by the compound, which is engineered to sneak past a cancer cell's membrane, then release an artemisinin "bomb" once inside.


A group of promising cancer-fighting compounds derived from a substance used in ancient Chinese medicine will be developed for potential use in humans, the University of Washington announced today.

The UW TechTransfer Office has signed a licensing agreement with Chongqing Holley Holdings, a Chinese company, and Holley Pharmaceuticals, its U.S. subsidiary.

The compounds, all developed through the research of UW scientists Henry Lai and Narendra Singh of the Department of Bioengineering and Tomikazu Sasaki of the Department of Chemistry, make use of a substance known as artemisinin, found in the wormwood plant and used throughout Asia since ancient times to treat malaria.

Although the compounds are promising, potential medical applications are still years away, officials say.

"We are very excited about the UW's discovery and an opportunity to develop an artemisinin-based cancer drug," Kevin Mak, chief scientist at Holley, said. "The technology is very promising, but it's in its early stages. Further research and clinical trials are needed."

The company, located in Chongqing, China, has been in the artemisinin business for more than 30 years, and is a world leader in farming, extracting and manufacturing artemisinin, its derivatives and artemisinin-based anti-malaria drugs, officials say.

Lai said he became interested in artemisinin about 10 years ago. The chemical helps control malaria because it reacts with the high iron concentrations found in the single-cell malaria parasite. When artemisinin comes into contact with iron, a chemical reaction ensues, spawning charged atoms that chemists call "free radicals." The free radicals attack the cell membrane and other molecules, breaking it apart and killing the parasite.

Lai said he began to wonder if the process might work with cancer, too.

"Cancer cells need a lot of iron to replicate DNA when they divide," Lai explained. "As a result, cancer cells have much higher iron concentrations than normal cells. When we began to understand how artemisinin worked, I started wondering if we could use that knowledge to target cancer cells."

Perhaps the most promising of the methods licensed involves the use of transferrin, to which the researchers bind artemisinin at the molecular level. Transferrin is an iron-carrying protein found in blood, and is transported into cells via transferrin receptors on a cell's surface.

Iron-hungry cancer cells typically have significantly more transferrin receptors on their surface than normal cells, which allows them to take in more of the iron-carrying protein. That, according to Lai, is what seems to make the compound so effective.

"We call it a Trojan horse because a cancer cell recognizes transferrin as a natural, harmless protein and picks up the tagged compound without knowing that a bomb -- artemisinin -- is hidden inside."

Once inside the cancer cell, the iron is released and reacts with the artemisinin. That makes the compound both highly toxic and, because of cancer's rapacious need for iron, highly selective. Surrounding, healthy cells are essentially undamaged.

"Our research in the lab indicated that the artemisinin-tagged transferrin was 34,000 times more effective in selecting and killing the cancer cells than normal cells," Lai said. "Artemisinin alone is 100 times more effective, so we've greatly enhanced the selectivity."

###

For more information, contact Lai at (206) 543-1071 or hlai@u.washington.edu. The Holley contact is Michael Liu, (714) 606-8415 or michael@holleypharma.com.


RELATED CONTENT FROM UWNEWS.ORG
  Ancient Chinese folk remedy may hold key to non-toxic cancer treatment
Nov. 26, 2001

MORE UWNEWS.ORG STORIES ABOUT HENRY LAI (mailto:hlai@u.washington.edu
RSS news feed: uwnews.org news releases about Henry Lai

  Ancient Chinese remedy shows potential in preventing breast cancer
Dec. 19, 2005
  Researchers blend folk treatment, high tech for promising anti-cancer compound
Feb. 8, 2005
  UW licenses potential cancer treatment derived from ancient Chinese folk remedy
Oct. 14, 2004
  Exposure to low-level magnetic fields causes DNA damage in rat brain cells, researchers find
Feb. 18, 2004
  Ancient Chinese folk remedy may hold key to non-toxic cancer treatment
Nov. 26, 2001
  Magnetic fields may hold key to malaria treatment, UW researchers find
March 30, 2000
  Rats exposed to cell phone microwaves suffer long-term memory loss, according to new study by a University of Washington researcher
Nov. 30, 1999


Quick Links: Maps | FAQ | Directories | UW Calendar | News | Admissions | Academics | Libraries | Employment

2007 University of Washington Office of News and Information  |  http://www.uwnews.org/
uwnews@u.washington.edu
phone:  206-543-2580     fax: 206-685-0658
Box 351207, Seattle WA, USA  98195.